European Commission approves BLENREP (belantamab mafodotin) for the treatment of patients with relapsed and refractory multiple myeloma
For media and investors only
Issued: London, UK- BLENREP is the first anti-BCMA (B-cell maturation antigen) therapy approved in the European Union
- Marketing authorisation follows the recent US approval of BLENREP